Abstract
Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have